3.53k followers • 19 symbols -2.37% Watchlist by Motif Investing
Successful drug approvals by the FDA and innovations in the treatment of cancer could provide relevant stocks a boost.
Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bristol-Myers Squibb (BMY) closed the most recent trading day at $53.08, moving -0.32% from the previous trading session.
The drug maker is down by a double-digit percentage so far this year, but BMO Capital Markets analyst Alex Arfaei lifted his rating to Outperform from Market Perform.
Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inovio (INO) to receive an undeclared milestone amount from AstraZeneca following the initiation of dosing in a phase II combo inspection of the latter's MEDI0457 for treating HPV-related cancers.
HealthEquity's (HQY) impressive results in Q3 can be attributed to solid growth in HSA Members. Its bullish guidance for fiscal 2019 further raises investors' optimism on the stock.
The FDA accepts and grants Priority Review to Roche's (RHHBY) sBLA for Tecentriq in combination with carboplatin and etoposide for the initial treatment of patients withextensive-stage small cell lung cancer.
Johnson & Johnson (JNJ) inks a global deal with Europe's argenx to jointly develop and globally commercialize the latter's prospective antibody, cusatuzumab.
Roche (RHHBY) announces new Venclexta/Venclyxto data that demonstrate deep responses in two of the most common types of leukaemia.
The alliance intends to develop an in vitro diagnostic (IVD) version of the Oncotype DX Genomic Prostate Score (GPS) test of Genomic Health (GHDX) on Biocartis' proprietary Idylla platform.
Accuray's (ARAY) benefits from growing adoption of non-surgical treatment options among cancer patients and increasing demand for its latest offerings.
In Bristol-Myers Squibb’s (BMY) third-quarter earnings conference call, the company estimated the contribution of RCC (renal cell carcinoma) indication to Opdivo’s US and ex-US market revenues to be close to 20% each.
In Bristol-Myers Squibb’s (BMY) third-quarter earnings conference call, the company estimated the contribution of melanoma indication to Opdivo’s US market revenues to be close to 30%. The contribution is ~20% in ex-US markets. The company expects the contribution of lung cancer indication to Opdivo’s revenues in ex-US markets to gradually decline as the drug penetrates deeper into other newly launched indications. Growth drivers
Bristol-Myers Squibb’s (BMY) Opdivo reported total revenues of $1.79 billion in the third quarter, which is a rise of 42% YoY (year-over-year). Among the revenues, the company earned $1.14 billion from the sale of Opdivo in the US market, which is a rise of 47% YoY.
Shire's (SHPG) gets European approval for Takhzyro subcutaneous injection, for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.